search
Back to results

Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients (rTMS)

Primary Purpose

Suicidal Ideation

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
repetitive transcranial magnetic stimulation (rTMS)
Sponsored by
University of Arkansas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Suicidal Ideation focused on measuring suicidality, rTMS, suicide ideation

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-60 years, of all races and ethnicities;
  • Admitted voluntarily to the adult psychiatric inpatient at PRI;
  • Suffering from a current depressive episode
  • Reason for hospitalization should be a recent suicide attempt or suicidal ideation
  • Current severe suicidal ideation defined by a score >7 on the Beck Scale for Suicidal Ideation
  • Ability to read, write and speak English.

Exclusion Criteria:

  • History of dementia, neurovascular or neurodegenerative conditions
  • Physical disabilities that prohibit task performance (such as blindness or deafness)
  • Choosing to opt out of the research study.
  • Additional exclusion criteria for TMS include the following:

    • a personal history or 1st degree relative with history of epilepsy;
    • a personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological, or migraines;
    • recent use of cocaine or alcohol;
    • ferromagnetic metal implants in the head or neck, active or inactive implants(including device leads), deep brain stimulators, cochlear implants or vagus nerve stimulators;
    • a pacemaker;
    • pregnancy (or the possibility of pregnancy);
    • Medications that lower seizure threshold (bupropion or tricyclic antidepressants, such as thorazine, clozapine, amitriptyline, amoxapine, Norpramin, Sinequan, Tofranil, Pamelor, Vivactil, or Surmontil). Other antidepressant and antipsychotic medications have been deemed exhibit a relatively low seizurogenic potential (Pisani et al. 2002).
    • Patients taking a medication for weight loss and depression called bupropion (Wellbutrin) they will be excluded because it may increase the likelihood of experiencing a seizure.

Sites / Locations

  • University of Arkansas for Medical Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Active rTMS

Sham rTMS

Arm Description

Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, defined as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a figure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).

Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.

Outcomes

Primary Outcome Measures

Beck Scale for Suicidal Ideation
Change in suicidal ideation between baseline assessment and following 3 day TMS trial.

Secondary Outcome Measures

Full Information

First Posted
February 12, 2016
Last Updated
April 30, 2021
Sponsor
University of Arkansas
search

1. Study Identification

Unique Protocol Identification Number
NCT02693743
Brief Title
Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients
Acronym
rTMS
Official Title
Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Terminated
Why Stopped
Study terminated early due to slow accrual or other non-safety related issues
Study Start Date
May 22, 2017 (Actual)
Primary Completion Date
February 28, 2019 (Actual)
Study Completion Date
February 28, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Arkansas

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Suicide was responsible for almost 40,000 deaths in 2011 in America. It is still singularly difficult to predict who is going to commit suicide and how to establish adequate interventions. Growing evidence supports the view that suicide is associated with poor decision making. Suicide is hypothesized to be triggered by stressful situations that create overwhelming psychological pain in an individual who chooses to terminate his/her own life, disregarding all future consequences. We have previously demonstrated rewarding impulsive choice common to both recent suicide attempters and suicidal depressed patients (1). Consistent with these findings, we hypothesize that high frequency repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal cortex will improve impulsive response tendencies as measured by the delay discounting procedure, and this in turn will be associated with a faster resolution of suicidal ideation. To these effects we will be using a randomized control trial of rTMS in adult inpatients at the Psychiatric Research Institute (PRI) hospitalized for acute suicidality. At the conclusion of these studies, we will have tested the value of decision making in the development of suicide ideation and behavior, as well as piloted the use of rTMS in the treatment of these patients.
Detailed Description
The proposed study seeks to improve the prevention of suicide by advancing our understanding of the neurobiology of suicide by using a randomized control trial of repetitive transcranial magnetic stimulation (rTMS) as a hypothesis driven intervention for acute suicidality. In 2010 suicide was responsible for more than 38,364 deaths in the United States and 447 in the state of Arkansas (CDC, 2012). Suicide represents the 10th leading cause of death in this country, and claims more deaths than chronic liver disease, hypertension, Parkinson's disease or homicide. Furthermore, suicide consequences extend beyond the termination of an individual's life to impact those that are left behind. These statistics are far more alarming because they are believed to be underestimates, with substantial numbers of suicides and suicide attempts undetected or misclassified. The high and rising prevalence of suicide is complicated by the clinical challenge of identifying those patients at highest risk for suicide. A variety of biological, psychological and social risk factors for suicide have been identified. However, we currently lack reliable predictors of suicide risk and must rely heavily upon self-report and clinical judgment. Thus, it remains singularly difficult to predict who is going to commit suicide. Therefore, there is an urgent unmet need to develop effective early detection methods and treatments for high-risk populations. Suicide has been described as "a permanent solution to a temporary problem" (Buchwald, 2006), reflecting the view that suicide is the result of poor decision making. The strongest biological finding in suicide research is the association with reduced serotonergic neurotransmission, particularly within the ventromedial prefrontal cortex (VMPFC) (Mann, 2003). This deficit in serotonergic neurotransmission is thought to impair cognition, predisposing patients to become more impulsive, rigid in their thinking, and poorer decision makers. Decisions during depressed states are tainted by negative affect and distorted negative cognitions (Martin-Soelch, 2009). However, suicide has been associated with cognitive impairments that go beyond those of depression. Asymptomatic patients with a history of suicide attempts exhibit significant cognitive deficits suggestive of generalized prefrontal cortex (PFC) dysfunction (Raust et al, 2007; Westheide et al, 2008), and corollary disruptions in risk assessment (Martino et al, 2010). Poor inhibition is found in suicide attempters when compared with patients with only suicidal ideation (Burton et al, 2011), and greater cognitive impairments are found in depressed patients with suicidal ideation compared to those without it (Dombrovski et al, 2010). It is possible that cognitive deficits may be specific to suicidal behavior rather than to any comorbid or specific psychiatric diagnosis because this observation holds true for suicidal patients with depression, bipolar disorder, and even temporal lobe epilepsy. However, most of these studies were performed in symptom-free patients, often months or years after the presence of suicidal ideation or behavior. In a previous report (Cáceda et al, 2014) we demonstrated that inability to delay gratification (choosing smaller immediate rewards over larger delayed rewards) is shared by both recent suicide attempters and depressed patients with suicidal ideation. On a follow up assessment, 5-10 days after the suicide attempt, reduction of suicidal ideation and intent was correlated with decreased symptoms of depression and recovery of delayed gratification impairments (Cáceda et al, 2014). These data are congruent with the hypothesis that stressful situations in combination with a biological and psychological predisposition may create a critical climate of overwhelming psychological pain in an individual who chooses an impulsive escapist strategy to terminate his/her own life discounting all future outcomes (Vohs et al, 2002). However, the underlying neural mechanisms remain unknown and therefore not amenable to therapeutic interventions. TMS is a noninvasive method to cause depolarization or hyperpolarization in the neurons in the brain using electromagnetic induction to induce weak electric currents using a rapidly changing magnetic field. TMS is a novel intervention developed in the field of neurology that has been used in the treatment of patients suffering from migraine, stroke, Parkinson's disease, tinnitus and depression. In healthy subjects, high frequency rTMS over the left DLPFC has been shown to alter impulsive choice behavior (to decrease delay discounting) in healthy individuals and in smokers (Sheffer et al, 2013). On the other hand, a trial of TMS by one of the leaders in the field has shown it to be safe and well tolerated in recent suicide attempters suffering from depression with comorbid post-traumatic stress disorder and traumatic brain injury (George et al, 2014). Dr. Mennemeier, the director of the Transcranial Magnetic Stimulation Laboratory in the Center for Translational Neuroscience has been using repetitive transcranial magnetic stimulation (rTMS) to understand and treat phantom sound perception in subjects with tinnitus and to examine risky choices and impulsive behaviors using delay discounting in smokers. We propose to replicate a randomized controlled trial of rTMS over 3 days in a sample of well characterized acutely suicidal inpatients. Our overall hypothesis is that 10 Hertz rTMS of the left dorsolateral prefrontal cortex (DLPFC) will correct impulsive choice behavior deficits found in acutely suicidal patients that in turn will translate into faster resolution of acute suicidal ideation. The current proposal will expand our understanding of the neurobiology of suicidal behavior by examining a potential neurocognitive mechanism of acute suicidality and test the value of rTMS as intervention for acute suicidal behavior. The current proposal will utilize behavioral assessments and rTMS in a randomized controlled trial in a group of adult patients hospitalized: a) following a recent suicide attempt with persistent suicidal ideation, or b) for severe suicidal ideation (n=20). Specifically, we propose: Specific Aim 1. Determine the safety of repetitive transcranial magnetic stimulation (rTMS) in depressed patients with severe suicidal ideation. Hypothesis 1: Given studies of rTMS for clinical depression, the investigators predict that rTMS in patients with severe suicidal ideation will be well tolerated and not associated with significant side effects. Specific Aim 2. Determine the effect of rTMS on delay discounting on depressed patients with severe suicidal ideation. Hypothesis 2: In depressed patients with severe suicidal ideation the rTMS active will reduce impulsive choice behavior (measured as delay discounting) compared with the non-treatment group. Specific Aim 3. Determine the effect of rTMS on suicidal ideation on depressed patients with severe suicidal ideation. Hypothesis 3.1: In depressed patients who had recently attempt suicide the rTMS active group will reduce suicidal ideation severity (measured by the Beck Scale for Suicidal Ideation) compared with the non-treatment group. Hypothesis 3.2: Suicidal ideation in depressed patients who recently attempt suicide will vary in function of delay discounting. Specific Aim 4. Identification of biomarkers of positive response to rTMS in depressed patients with severe suicidal ideation. Hypothesis 4: A composite of serum hormonal and inflammatory markers will predict positive response to rTMS in depressed patients with severe suicidal ideation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Suicidal Ideation
Keywords
suicidality, rTMS, suicide ideation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active rTMS
Arm Type
Active Comparator
Arm Description
Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, defined as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a figure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
Arm Title
Sham rTMS
Arm Type
Sham Comparator
Arm Description
Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
Intervention Type
Device
Intervention Name(s)
repetitive transcranial magnetic stimulation (rTMS)
Intervention Description
A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
Primary Outcome Measure Information:
Title
Beck Scale for Suicidal Ideation
Description
Change in suicidal ideation between baseline assessment and following 3 day TMS trial.
Time Frame
Within the 3 days of the TMS trial.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-60 years, of all races and ethnicities; Admitted voluntarily to the adult psychiatric inpatient at PRI; Suffering from a current depressive episode Reason for hospitalization should be a recent suicide attempt or suicidal ideation Current severe suicidal ideation defined by a score >7 on the Beck Scale for Suicidal Ideation Ability to read, write and speak English. Exclusion Criteria: History of dementia, neurovascular or neurodegenerative conditions Physical disabilities that prohibit task performance (such as blindness or deafness) Choosing to opt out of the research study. Additional exclusion criteria for TMS include the following: a personal history or 1st degree relative with history of epilepsy; a personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological, or migraines; recent use of cocaine or alcohol; ferromagnetic metal implants in the head or neck, active or inactive implants(including device leads), deep brain stimulators, cochlear implants or vagus nerve stimulators; a pacemaker; pregnancy (or the possibility of pregnancy); Medications that lower seizure threshold (bupropion or tricyclic antidepressants, such as thorazine, clozapine, amitriptyline, amoxapine, Norpramin, Sinequan, Tofranil, Pamelor, Vivactil, or Surmontil). Other antidepressant and antipsychotic medications have been deemed exhibit a relatively low seizurogenic potential (Pisani et al. 2002). Patients taking a medication for weight loss and depression called bupropion (Wellbutrin) they will be excluded because it may increase the likelihood of experiencing a seizure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pedro L Delgado, MD
Organizational Affiliation
University of Arkansas
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Arkansas for Medical Sciences
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24988311
Citation
Caceda R, Durand D, Cortes E, Prendes-Alvarez S, Moskovciak T, Harvey PD, Nemeroff CB. Impulsive choice and psychological pain in acutely suicidal depressed patients. Psychosom Med. 2014 Jul-Aug;76(6):445-51. doi: 10.1097/PSY.0000000000000075.
Results Reference
background
PubMed Identifier
26804777
Citation
Heins SE, Crifasi CK. Distinctive injury deaths: the role of environment, policy and measurement across states. Inj Prev. 2016 Aug;22(4):247-52. doi: 10.1136/injuryprev-2015-041833. Epub 2016 Jan 24.
Results Reference
background
Citation
Buchwald A. Too soon to say goodbye. 1st ed. New York: Random house; 2006.
Results Reference
background
PubMed Identifier
14523381
Citation
Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci. 2003 Oct;4(10):819-28. doi: 10.1038/nrn1220. No abstract available.
Results Reference
background
PubMed Identifier
19143654
Citation
Martin-Soelch C. Is depression associated with dysfunction of the central reward system? Biochem Soc Trans. 2009 Feb;37(Pt 1):313-7. doi: 10.1042/BST0370313.
Results Reference
background
PubMed Identifier
18330667
Citation
Westheide J, Quednow BB, Kuhn KU, Hoppe C, Cooper-Mahkorn D, Hawellek B, Eichler P, Maier W, Wagner M. Executive performance of depressed suicide attempters: the role of suicidal ideation. Eur Arch Psychiatry Clin Neurosci. 2008 Oct;258(7):414-21. doi: 10.1007/s00406-008-0811-1. Epub 2008 Mar 11.
Results Reference
background
PubMed Identifier
17049103
Citation
Raust A, Slama F, Mathieu F, Roy I, Chenu A, Koncke D, Fouques D, Jollant F, Jouvent E, Courtet P, Leboyer M, Bellivier F. Prefrontal cortex dysfunction in patients with suicidal behavior. Psychol Med. 2007 Mar;37(3):411-9. doi: 10.1017/S0033291706009111. Epub 2006 Oct 19.
Results Reference
background
PubMed Identifier
20860871
Citation
Martino DJ, Strejilevich SA, Torralva T, Manes F. Decision making in euthymic bipolar I and bipolar II disorders. Psychol Med. 2011 Jun;41(6):1319-27. doi: 10.1017/S0033291710001832. Epub 2010 Sep 22.
Results Reference
background
PubMed Identifier
21677246
Citation
Burton CZ, Vella L, Weller JA, Twamley EW. Differential effects of executive functioning on suicide attempts. J Neuropsychiatry Clin Neurosci. 2011 Spring;23(2):173-9. doi: 10.1176/jnp.23.2.jnp173.
Results Reference
background
PubMed Identifier
20231320
Citation
Dombrovski AY, Clark L, Siegle GJ, Butters MA, Ichikawa N, Sahakian BJ, Szanto K. Reward/Punishment reversal learning in older suicide attempters. Am J Psychiatry. 2010 Jun;167(6):699-707. doi: 10.1176/appi.ajp.2009.09030407. Epub 2010 Mar 15.
Results Reference
background
Citation
Vohs KD, Baumeister R. Escaping the self consumes regulatory resources: a self-regulatory model of suicide. Suicide Science. 2002:33-41.
Results Reference
background
PubMed Identifier
23518286
Citation
Sheffer CE, Mennemeier M, Landes RD, Bickel WK, Brackman S, Dornhoffer J, Kimbrell T, Brown G. Neuromodulation of delay discounting, the reflection effect, and cigarette consumption. J Subst Abuse Treat. 2013 Aug;45(2):206-14. doi: 10.1016/j.jsat.2013.01.012. Epub 2013 Mar 18.
Results Reference
background
PubMed Identifier
24731434
Citation
George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes KT, Schmidt M, Spiegel C, Dealmeida N, Beaver KL, Borckardt JJ, Sun X, Jain S, Stein MB. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul. 2014 May-Jun;7(3):421-31. doi: 10.1016/j.brs.2014.03.006. Epub 2014 Mar 19.
Results Reference
background
PubMed Identifier
22193671
Citation
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.
Results Reference
background
PubMed Identifier
14399272
Citation
HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56. No abstract available.
Results Reference
background
Citation
Hamilton M. Diagnosis and rating of anxiety. The British journal of psychiatry : the journal of mental science. 1969;3:76-9.
Results Reference
background
PubMed Identifier
469082
Citation
Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979 Apr;47(2):343-52. doi: 10.1037//0022-006x.47.2.343. No abstract available.
Results Reference
background
Citation
Beck AT. Beck Hopelessness Scale. The Psychological Corporation; 1988.
Results Reference
background
PubMed Identifier
10100392
Citation
Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen. 1999 Mar;128(1):78-87. doi: 10.1037//0096-3445.128.1.78.
Results Reference
background
PubMed Identifier
15846822
Citation
Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp. 2005 May;25(1):46-59. doi: 10.1002/hbm.20131.
Results Reference
background
PubMed Identifier
22781400
Citation
Keilp JG, Gorlyn M, Russell M, Oquendo MA, Burke AK, Harkavy-Friedman J, Mann JJ. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013 Mar;43(3):539-51. doi: 10.1017/S0033291712001419. Epub 2012 Jul 10.
Results Reference
background
PubMed Identifier
13263471
Citation
REITAN RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955 Oct;19(5):393-4. doi: 10.1037/h0044509. No abstract available.
Results Reference
background
PubMed Identifier
9661090
Citation
Pridmore S, Fernandes Filho JA, Nahas Z, Liberatos C, George MS. Motor threshold in transcranial magnetic stimulation: a comparison of a neurophysiological method and a visualization of movement method. J ECT. 1998 Mar;14(1):25-7.
Results Reference
background
PubMed Identifier
15343000
Citation
Mishory A, Molnar C, Koola J, Li X, Kozel FA, Myrick H, Stroud Z, Nahas Z, George MS. The maximum-likelihood strategy for determining transcranial magnetic stimulation motor threshold, using parameter estimation by sequential testing is faster than conventional methods with similar precision. J ECT. 2004 Sep;20(3):160-5. doi: 10.1097/00124509-200409000-00007.
Results Reference
background
PubMed Identifier
16957531
Citation
Borckardt JJ, Nahas Z, Koola J, George MS. Estimating resting motor thresholds in transcranial magnetic stimulation research and practice: a computer simulation evaluation of best methods. J ECT. 2006 Sep;22(3):169-75. doi: 10.1097/01.yct.0000235923.52741.72.
Results Reference
background
PubMed Identifier
19833552
Citation
Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14.
Results Reference
background
PubMed Identifier
17314192
Citation
Rossi S, De Capua A, Ulivelli M, Bartalini S, Falzarano V, Filippone G, Passero S. Effects of repetitive transcranial magnetic stimulation on chronic tinnitus: a randomised, crossover, double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):857-63. doi: 10.1136/jnnp.2006.105007. Epub 2007 Feb 21.
Results Reference
background
PubMed Identifier
20633385
Citation
Langguth B, de Ridder D, Dornhoffer JL, Eichhammer P, Folmer RL, Frank E, Fregni F, Gerloff C, Khedr E, Kleinjung T, Landgrebe M, Lee S, Lefaucheur JP, Londero A, Marcondes R, Moller AR, Pascual-Leone A, Plewnia C, Rossi S, Sanchez T, Sand P, Schlee W, Pysch D, Steffens T, van de Heyning P, Hajak G. Controversy: Does repetitive transcranial magnetic stimulation/ transcranial direct current stimulation show efficacy in treating tinnitus patients? Brain Stimul. 2008 Jul;1(3):192-205. doi: 10.1016/j.brs.2008.06.003. Epub 2008 Jul 1.
Results Reference
background
PubMed Identifier
9474057
Citation
Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16. doi: 10.1016/s0168-5597(97)00096-8.
Results Reference
background
PubMed Identifier
7683602
Citation
Pascual-Leone A, Houser CM, Reese K, Shotland LI, Grafman J, Sato S, Valls-Sole J, Brasil-Neto JP, Wassermann EM, Cohen LG, et al. Safety of rapid-rate transcranial magnetic stimulation in normal volunteers. Electroencephalogr Clin Neurophysiol. 1993 Apr;89(2):120-30. doi: 10.1016/0168-5597(93)90094-6.
Results Reference
background
PubMed Identifier
8080978
Citation
Grafman J, Pascual-Leone A, Alway D, Nichelli P, Gomez-Tortosa E, Hallett M. Induction of a recall deficit by rapid-rate transcranial magnetic stimulation. Neuroreport. 1994 May 9;5(9):1157-60. doi: 10.1097/00001756-199405000-00034.
Results Reference
background
PubMed Identifier
9443476
Citation
Flitman SS, Grafman J, Wassermann EM, Cooper V, O'Grady J, Pascual-Leone A, Hallett M. Linguistic processing during repetitive transcranial magnetic stimulation. Neurology. 1998 Jan;50(1):175-81. doi: 10.1212/wnl.50.1.175.
Results Reference
background
PubMed Identifier
2027485
Citation
Pascual-Leone A, Gates JR, Dhuna A. Induction of speech arrest and counting errors with rapid-rate transcranial magnetic stimulation. Neurology. 1991 May;41(5):697-702. doi: 10.1212/wnl.41.5.697.
Results Reference
background
PubMed Identifier
2381522
Citation
Counter SA, Borg E, Lofqvist L, Brismar T. Hearing loss from the acoustic artifact of the coil used in extracranial magnetic stimulation. Neurology. 1990 Aug;40(8):1159-62. doi: 10.1212/wnl.40.8.1159.
Results Reference
background
PubMed Identifier
21287564
Citation
Mennemeier M, Chelette KC, Allen S, Bartel TB, Triggs W, Kimbrell T, Crew J, Munn T, Brown GJ, Dornhoffer J. Variable changes in PET activity before and after rTMS treatment for tinnitus. Laryngoscope. 2011 Apr;121(4):815-22. doi: 10.1002/lary.21425. Epub 2011 Feb 1.
Results Reference
background
PubMed Identifier
18475211
Citation
Mennemeier M, Chelette KC, Myhill J, Taylor-Cooke P, Bartel T, Triggs W, Kimbrell T, Dornhoffer J. Maintenance repetitive transcranial magnetic stimulation can inhibit the return of tinnitus. Laryngoscope. 2008 Jul;118(7):1228-32. doi: 10.1097/MLG.0b013e318170f8ac.
Results Reference
background
PubMed Identifier
20160893
Citation
Mennemeier M, Triggs W, Chelette K, Woods A, Kimbrell T, Dornhoffer J. Sham Transcranial Magnetic Stimulation Using Electrical Stimulation of the Scalp. Brain Stimul. 2009 Jul 1;2(3):168-173. doi: 10.1016/j.brs.2009.02.002.
Results Reference
background
PubMed Identifier
17334317
Citation
Smith JA, Mennemeier M, Bartel T, Chelette KC, Kimbrell T, Triggs W, Dornhoffer JL. Repetitive transcranial magnetic stimulation for tinnitus: a pilot study. Laryngoscope. 2007 Mar;117(3):529-34. doi: 10.1097/MLG.0b013e31802f4154.
Results Reference
background
PubMed Identifier
1373364
Citation
Roth BJ, Pascual-Leone A, Cohen LG, Hallett M. The heating of metal electrodes during rapid-rate magnetic stimulation: a possible safety hazard. Electroencephalogr Clin Neurophysiol. 1992 Apr;85(2):116-23. doi: 10.1016/0168-5597(92)90077-o.
Results Reference
background
Citation
Pascual-Leone A. Handbook of transcranial magnetic stimulation. London New York, NY: Arnold ; Oxford University Press distributor; 2002.
Results Reference
background
PubMed Identifier
10636165
Citation
Niehaus L, Hoffmann KT, Grosse P, Roricht S, Meyer BU. MRI study of human brain exposed to high-dose repetitive magnetic stimulation of visual cortex. Neurology. 2000 Jan 11;54(1):256-8. doi: 10.1212/wnl.54.1.256.
Results Reference
background

Learn more about this trial

Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients

We'll reach out to this number within 24 hrs